Report cover image

Global Market for At-Home and Home Collection In Vitro Diagnostic (IVD) Testing, 2025–2030

Publisher Kalorama Information
Published Oct 01, 2025
Length 125 Pages
SKU # KLI20513624

Description

The convenience revolution in healthcare has arrived—and diagnostics are at the center of it. The Global Market for At-Home and Home Collection In Vitro Diagnostic (IVD) Testing, 2025–2030 provides a comprehensive analysis of one of the fastest-evolving sectors of the diagnostics industry. Covering both self-administered over-the-counter (OTC) tests and home collection kits analyzed in central laboratories, this Kalorama Information report examines the technologies, market forces, and consumer behaviors transforming how patients engage with testing and care.

For diagnostic developers, investors, and healthcare strategists, The Global Market for At-Home and Home Collection In Vitro Diagnostic (IVD) Testing, 2025–2030 provides the essential insight needed to understand how home diagnostics are moving beyond niche applications to become a core component of modern healthcare delivery—and a key driver of the global IVD market’s future growth.

Building on the momentum sparked by the COVID-19 pandemic, the report explores how growing public confidence in self-testing is reshaping the landscape of infectious disease detection, chronic disease management, oncology, genetic testing, and wellness screening. While glucose monitoring and pregnancy testing continue to anchor the category, innovations in non-invasive sampling methods—from saliva and urine to breath analysis—are enabling a broader range of tests to move from clinic to home.

The global Home IVD testing market is segmented into several broad areas, including:
  • Genetic
  • Glucose/ HbA1c
  • Infectious disease
  • Other areas
  • Pregnancy and Fertility
  • Coagulation
  • Fecal Occult Blood
  • Cholesterol
  • Drugs of Abuse
Each market segment includes a detailed analysis of regulatory trends, clinical practices, and recent product approvals, along with 2025 sales data and forecasts through 2030 across major world regions, including the United States, EMEA, Asia Pacific, and the Rest of World. The study profiles key market leaders and emerging competitors, evaluating how technological advances, consumer acceptance, and cost considerations will drive growth and shape competition.

The report also distinguishes between the two major segments:
  • At-Home IVD Tests – fully self-administered tests providing immediate results (e.g., pregnancy and glucose monitoring).
  • Home Collection IVD Tests – tests where patients collect samples and send them to a laboratory for analysis (e.g., fecal occult blood, genetic, and infectious disease testing).
Scope and Methodology

Using a combination of primary interviews and secondary research, the report delivers reliable market sizing, competitive intelligence, and growth projections based on 2025 as the base year. Forecasts through 2030 include compound annual growth rates (CAGRs) and regional performance indicators.

Despite the growing demand, the report also acknowledges ongoing challenges in cost-benefit analysis, reimbursement models, and regulatory and privacy frameworks that may shape the pace of adoption.

Please Note: Single user allows for up to 3 users for this report.

Table of Contents

125 Pages
CHAPTER 1: EXECUTIVE SUMMARY
INDUSTRY AT A GLANCE
SIZE AND GROWTH OF THE MARKET
Figure 1-1: Global Home IVD Market by Key Segment, 2022-2025 ($ million) [Genetic, Glucose/HbA1c, Infectious Disease, Other Areas]
KEY ISSUES AND TRENDS AFFECTING THE MARKET
COMPETITIVE OUTLOOK
CONCLUSION HIGHLIGHTS
ABOUT KALORAMA INFORMATION
CHAPTER 2: INTRODUCTION
HOME IVD TESTING OVERVIEW
Market Segments
Market Evolution
Historical Context
Market Drivers
Key Players
ISSUES AND TRENDS
COVID-19 Evolution
Figure 2-1: Home COVID-19 Test Distribution of Sales, by Vendor, 2025 (%)
Reimbursement for Home Tests
Continuous Glucose Monitors
Figure 2-2: Continuous Glucose Monitor Access for Medicaid Beneficiaries Living with Diabetes: State-By-State Coverage
Infectious Disease
Cancer
Chronic Disease Monitoring
Genetic
Home IVD Testing Drivers and Challenges
Figure 2-3: Benefits and Challenges to Home Testing, 2025
Key Benefits of Home Testing
Key Challenges of Home Testing
GENETICS
Table 2-1: Home Genetic Laboratory Testing, Market Drivers and Barriers
HOME COLLECTION
CHAPTER 3: AT-HOME IVD TESTS
INTRODUCTION
Diabetes
Table 3-1: Selected Glucose At-Home Testing Meter Innovations
Pregnancy and Fertility
Infectious Disease
HIV
COVID-19 & Flu
Table 3-2: Selected Molecular COVID-19 and COVID-19 & Flu A/B At-Home Tests for SARS-CoV-2, 2024-2025
Table 3-3: Selected Antigen COVID- 19 and COVID-19 & Flu A/B At-Home Tests for SARS-CoV-2, 2024-2025
Coagulation
Fecal Occult Blood
Cholesterol
Drugs of Abuse
AT-HOME IVD TEST MARKET BY TEST TYPE
Table 3-4: Global At-Home IVD Market, by Test Type, 2025 ($ billion) [Glucose, Infectious Disease, Other]
Figure 3-1: Global At-Home IVD Market by Distribution of Sales, by Segment, 2025 (%) [Cholesterol, Coagulation, COVID-19+, Drug of Abuse, FOB, Glucose, HIV, Other Infections, Pregnancy & Fertility, Other]
AT-HOME IVD TESTS MARKET BY SAMPLE TYPE
Table 3-5: Global At-Home IVD Market, by Sample Type, 2025 ($ billion) [Blood, Interstitial Fluid, Nasal, Oral/Saliva, Stool, Urine, Other]
Figure 3-2: Global At-Home IVD Market by Distribution of Sales, by Sample Type, 2020 and 2025 (%) [Blood, Interstitial Fluid, Nasal, Oral/Saliva, Stool, Urine, Other]
Figure 3-3: Year-over-Year Growth for At-Home IVD Markets, '23-24 & '24-25 (%) [Cholesterol, Coagulation, COVID-19, Drugs of Abuse, Fecal Occult Blood (FOB), Glucose, HIV, Infectious Disease, Pregnancy & Fertility, Other]
Blood Samples
Figure 3-4: Estimated Distribution of Blood Sample Sales, by Test Type, 2025 (%) [Cholesterol, Coagulation, Glucose, Other]
Interstitial Fluid Samples
Urine Samples
Figure 3-5: Estimated Distribution of Urine Sample Sales, by Test Type, 2025 (%) [Drugs of Abuse, Infectious Disease, Pregnancy, Other]
Oral/Saliva Samples
Figure 3-6: Estimated Distribution of Oral/Saliva Sample Sales, by Test Type, 2025 (%) [COVID-19, Drugs of Abuse, HIV, Other]
Nasal Samples
Figure 3-7: Estimated Distribution of Nasal Sample Sales, by Test Type, 2025 (%) [COVID-19, Other]
Stool Samples
Figure 3-8: Estimated Distribution of Stool Sample Sales, by Test Type, 2025 (%) [Fecal Occult Blood (FOB), Other]
Other
CHAPTER 4: HOME COLLECTION IVD TESTS
INTRODUCTION
Pregnancy and Fertility
Infectious Disease
HIV
HPV and Other STDs
Hepatitis
COVID-19
COVID-19 & Flu
Fecal Occult Blood
Cholesterol
Genetics
Other
HOME COLLECTION IVD TEST MARKET BY TEST TYPE
Table 4-1: Global Home Collection IVD Market, by Test Type, 2025 ($ billion) [Genetics, Infectious Disease, Other Areas]
Figure 4-1: Global Home IVD Market by Distribution of Sales, by Segment, 2025 (%) [Cholesterol, Coagulation, COVID-19, Drug of Abuse, FOB, Glucose, HbA1c, HIV, Other Infections, Pregnancy & Fertility, Other]
Privacy Genetic Testing
HOME COLLECTION TESTS MARKET BY SAMPLE TYPE
Table 4-2: Global Home Collection IVD Market, by Sample Type, 2025 ($ billion) [Blood, Nasal, Oral/Saliva, Stool, Urine, Other]
Figure 4-2: Global Home Collection IVD Market by Distribution of Sales, by Sample Type, 2020 and 2025 (%) [Blood, Nasal, Oral/Saliva, Stool, Urine, Other]
Figure 4-3: Year-over-Year Growth for Home Collection IVD Markets, '23-24 and '24-25 (%) [Cholesterol, Coagulation, COVID-19, Drugs of Abuse, Fecal Occult Blood (FOB), Genetic, HbA1c, HIV, Infectious Disease, Pregnancy & Fertility, Other]
Blood Samples
Figure 4-4: Estimated Distribution of Blood Sample Sales, by Test Type, 2025 (%) [Cholesterol, Fertility, Genetic, Glucose/HbA1c, Infectious Disease – STD Blood Spot, Tumor Marker – PSA Blood Spot, Other - Hormone]
Urine Samples
Figure 4-5: Estimated Distribution of Urine Sample Sales, by Test Type, 2025 (%) [Infectious Disease – STD, Pregnancy/Fertility, Other – Heavy Metals, Hormone, Nutrition]
Oral/Saliva Samples
Figure 4-6: Estimated Distribution of Oral/Saliva Sample Sales, by Test Type, 2025 (%) [COVID-19, Drugs of Abuse, Fertility, Genetic, HIV, Other – Hormone, Nutrition, Medication Match]
Nasal Samples
Figure 4-7: Estimated Distribution of Nasal Sample Sales, by Test Type, 2025 (%) [COVID-19, Other]
Stool Samples
Figure 4-8: Estimated Distribution of Stool Sample Sales, by Test Type, 2025 (%) [Fecal Occult Blood (FOB), Infectious Disease – Pathogen ID, Other – Heavy Metals]
Other
CHAPTER 5: MARKET PARTICIPANTS
23ANDME, INC
Table 5-1: 23andMe Corporate Summary
Company Overview
Table 5-2: 23andMe Genetic Tests with FDA Marketing Authorization
ABBOTT DIAGNOSTICS
Table 5-3: Corporate Summary
Company Overview
Performance Review
Table 5-4: Abbott Revenues, 2020-2024 ($ million)
ABINGDON HEALTH LTD.
Table 5-5: Abingdon Health Corporate Summary
Company Overview
ACON LABORATORIES, INC.
Table 5-6: ACON Laboratories Corporate Summary
Company Overview
ARKRAY, INC.
Table 5-7: ARKRAY Corporate Summary
Company Overview
ASCENSIA DIABETES CARE HOLDINGS AG
Table 5-8: Ascensia Diabetes Care Corporate Summary
Company Overview
ATOMO DIAGNOSTICS
Table 5-9: Atomo Corporate Summary
Company Overview
BECTON DICKINSON
Table 5-10: Becton Dickinson Corporate Summary
Company Overview
Performance Review
Table 5-11: BD Corporation Revenue, 2020-2024 ($ billion)
BINX HEALTH
Table 5-12: binx health Corporate Summary
Company Overview
BIOMERICA, INC.
Table 5-13: Biomerica Corporate Summary
Company Overview
Company Financials
Table 5-14: Biomerica Corporation Revenue, 2020-2024 ($ million)
BIOSYNEX SA
Table 5-15: Biosynex Corporate Summary
Company Overview
CHURCH & DWIGHT CO. INC
Table 5-16: Church & Dwight Corporate Summary
Company Overview
Performance Review
Table 5-17: Church and Dwight Revenues, 2020-2024 ($ million)
COLOR HEALTH, INC.
Table 5-18: Color Health Corporate Summary
Company Overview
DEXCOM, INC.
Table 5-19: Dexcom Corporation Corporate Summary
Company Overview
Performance Review
Table 5-20: Dexcom Revenues, 2020-2024 ($ million)
EASYDNA
Table 5-21: EasyDNA Corporate Summary
Company Overview
EVERLY HEALTH
Table 5-22: Everly Health Corporate Summary
Company Overview
EXACT SCIENCES
Table 5-23: Exact Sciences Corporate Summary
Company Overview
Performance Review
Table 5-24: Exact Sciences Revenues (2020-2024) ($ million)
GENEDX
Table 5-25: GeneDx Corporate Summary
Company Overview
HELENA LABORATORIES
Table 5-26: Helena Laboratories Corporate Summary
Company Overview
HEMOSURE, INC.
Table 5-27: Hemosure Corporate Summary
Company Overview
LABORATORY CORPORATION OF AMERICA
Table 5-28: Laboratory Corporation of America Corporate Details
Company Overview
Performance Review
Table 5-29: Labcorp Revenue History, 2020-2024 ($ million)
MEDICHECKS.COM LTD.
Table 5-30: Medichecks Corporate Summary
Company Overview
MYRIAD GENETICS, INC.
Table 5-31: Myriad Genetics Corporate Summary
Company Overview
Performance Review
Table 5-32: Myriad Diagnostics Revenue, 2020-2024 ($ million)
NATERA
Table 5-33: Natera Corporate Summary
Company Overview
Performance Review
Table 5-34: Natera Revenue History, 2020-2024 ($ million)
ORASURE TECHNOLOGIES, INC.
Table 5-35: OraSure Technologies Summary
Company Overview
Performance Review
Table 5-36: OraSure Revenues, 2020-2024 ($ million)
POLYMEDCO, INC
Table 5-37: Polymedco Corporate Summary
Company Overview
PREVENTIS GMBH
Table 5-38: Preventis Corporate Summary
Company Overview
PRIMA LAB SA
Table 5-39: Prima Corporate Summary
Company Overview
QUEST DIAGNOSTICS, INC.
Table 5-40: Quest Diagnostics Corporate Details
Company Overview
Performance Review
Table 5-41: Quest Diagnostics Revenue History, 2020-2024 ($ million)
QUIDELORTHO CORPORATION
Table 5-42: QuidelOrtho Corporate Summary
Company Overview
Performance Review
Table 5-43: QuidelOrtho Revenues, 2020-2024 ($ million)
ROCHE DIAGNOSTIC CORPORATION
Table 5-44: Roche Diagnostic Corporate Summary
Company Overview
Performance Review
Table 5-45: Roche Diagnostics, 2020-2024 (CHF billion)
SIEMENS HEALTHINEERS GMBH
Table 5-46: Siemens Healthineers Corporate Summary
Company Overview
Performance Review
Table 5-47: Siemens Healthineers Revenue History, 2020-2024 (€ million)
SWISS PRECISION DIAGNOSTICS GMBH
Table 5-48: Swiss Precision Diagnostics Corporate Summary
Company Overview
TRIVIDIA HEALTH
Table 5-49: Trividia Health Corporate Summary
Company Overview
VEDALAB
Table 5-50: VedaLab Corporate Summary
Company Overview
CHAPTER 6: MARKET ANALYSIS
MARKET OVERVIEW
Figure 6-1: Global Home IVD Market, 2025-2030 ($ million) [Genetic, Infectious Disease, Other Areas]
MARKET SEGMENT BY TEST TYPE
Figure 6-2: Global Home IVD Market by Test Type, 2022-2025 ($ million) [Genetic, Glucose/HbA1c, Infectious Disease, Other Areas]
Figure 6-3: Global Home IVD Market, by General Test Segment, 2025 (%) [Genetic, Glucose/HbA1c, Infectious Disease, Other Areas]
Glucose & HbA1c
Table 6-1: Estimated Global Home IVD Glucose & HbA1c Testing Market, 2025-2030 ($ million)
Infectious Disease
Table 6-2: Estimated Global Home IVD Infectious Disease Testing Market, 2025-2030 ($ million)
Genetic
Table 6-3: Estimated Global Home IVD Genetic Testing Market, 2025-2030 ($ million)
Other Areas
Table 6-4: Estimated Global Home IVD Other Testing Market, 2025-2030 ($ million)
MARKET BY DISTRIBUTION
MARKET BY REGION
Figure 6-4: Estimated Global Home IVD Testing Market, by Region, 2023-2025 ($ million) [APAC, EMEA, United States, Rest of World]
COMPETITIVE ANALYSIS
Figure 6-5: Estimated Global Home IVD Testing Market, Top Vendor Market Share, 2025 (%)

Search Inside Report

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us